Top Page
IVD Medical Holding Limited
(1931)
IVD Medical Holding Limited (1931) vs. iShares MSCI Hong Kong ETF (EWH)
IVD Medical Holding Limited Business Overview & Revenue Model
IVD Medical Holding Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.08B | 3.16B | 3.09B | 2.75B | 2.73B | 2.43B |
| Gross Profit | 706.08M | 751.17M | 671.70M | 608.14M | 566.27M | 476.17M |
| EBITDA | 401.57M | 475.96M | 397.93M | 349.66M | 286.17M | 250.04M |
| Net Income | 174.25M | 260.42M | 238.16M | 210.00M | 174.54M | 158.72M |
Balance Sheet | ||||||
| Total Assets | 6.16B | 5.52B | 4.79B | 4.31B | 4.37B | 3.91B |
| Cash, Cash Equivalents and Short-Term Investments | 427.55M | 1.86B | 1.24B | 1.04B | 841.78M | 794.74M |
| Total Debt | 1.67B | 755.97M | 344.32M | 349.92M | 427.65M | 421.80M |
| Total Liabilities | 2.63B | 1.76B | 1.40B | 1.16B | 1.37B | 1.05B |
| Stockholders Equity | 3.47B | 3.71B | 3.34B | 3.15B | 2.98B | 2.85B |
Cash Flow | ||||||
| Free Cash Flow | 99.21M | 88.69M | 251.92M | 215.39M | 137.88M | 144.87M |
| Operating Cash Flow | 136.55M | 140.29M | 292.42M | 249.67M | 163.11M | 170.49M |
| Investing Cash Flow | -2.00M | -57.80M | -77.58M | 60.54M | -27.88M | -196.00M |
| Financing Cash Flow | -18.46M | 395.13M | -19.45M | -191.29M | -66.29M | -63.24M |
IVD Medical Holding Limited Technical Analysis
IVD Medical Holding Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$9.84B | 27.93 | 6.77% | 2.72% | 29.81% | 10.40% | |
72 Outperform | HK$63.79B | 8.68 | 8.74% | 3.75% | -2.68% | -21.45% | |
71 Outperform | HK$65.65B | 7.23 | 7.53% | 2.67% | 2.77% | 39.24% | |
62 Neutral | HK$3.53B | 18.79 | 5.07% | 3.81% | 0.33% | -44.28% | |
60 Neutral | HK$786.24M | 15.08 | 8.12% | 8.03% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$649.87M | -0.59 | -69.05% | ― | -43.86% | -217.25% |
IVD Medical Holding Limited Corporate Events
ETHK Labs Inc. has announced substantial changes to its leadership and governance structure effective 13 January 2026, with the resignation of executive directors Mr. Law Kim Fai and Ms. Tai Yang, and independent non-executive director Mr. Wong Sze Lok, alongside Mr. Law stepping down as chief financial officer, company secretary and authorised representative. In response, the company has reshuffled key board committees, appointing Mr. Zhang Jianlei as chairman of both the audit and remuneration committees, adding Mr. Chan Siu Kei Ken to the nomination committee and naming him company secretary, and appointing Mr. Zhong Renqian and Mr. Xu Da to the remuneration committee. The changes leave the nomination committee temporarily without gender diversity as required under Hong Kong’s corporate governance code, and the board has indicated it will review the committee’s composition, underscoring ongoing governance obligations and the importance of maintaining regulatory compliance amid senior management turnover.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
ETHK Labs Inc. has announced the current composition of its board of directors and the allocation of roles across key board committees, formalizing its governance framework for investors and stakeholders. The board consists of two executive directors, two non-executive directors and three independent non-executive directors, with independent director Zhang Jianlei appointed as chairman of the audit, remuneration and nomination committees, and other independent directors serving as members, underscoring an emphasis on independent oversight and alignment with corporate governance best practices in the Hong Kong market.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited announced that during its extraordinary general meeting held on November 26, 2025, a special resolution to change the company’s English name was passed with unanimous support. This decision reflects a strategic move that could impact the company’s brand identity and market positioning, potentially influencing stakeholder perceptions and future business operations.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced its acquisition of a significant stake in B-Soft Co., Ltd, a move that positions the company to hold approximately 12.64% of the voting rights in B-Soft. This strategic acquisition, valued at RMB500 million, involves the purchase of 96,525,096 A shares, representing 6.23% of B-Soft’s total issued share capital. Additionally, the company has secured voting rights for an additional 195,780,282 A shares through agreements with the vendor and a private fund. This transaction is classified as a discloseable transaction under Chapter 14 of the Listing Rules, requiring reporting and announcement but exempt from shareholder approval. The acquisition is contingent on regulatory approvals and other conditions, and stakeholders are advised to exercise caution.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced that it is in discussions to potentially acquire control over B-Soft Co., Ltd., a company listed on the ChiNext Board of the Shenzhen Stock Exchange. The transaction, if completed, could significantly impact IVD Medical’s market positioning by expanding its influence in the Chinese market. However, the transaction is still under negotiation, and there are various conditions and approvals required before it can proceed. Shareholders are advised to exercise caution as the deal may not materialize.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced an extraordinary general meeting scheduled for November 26, 2025, to consider a special resolution for changing its English name to ETHK Labs Inc. This change, pending approval from the Cayman Islands Registrar of Companies, signifies a strategic rebranding effort that could impact the company’s market positioning and stakeholder perception.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited announced significant strategic advancements, including the development of the ivd.xyz Exchange, the world’s first real-world asset exchange ecosystem for medical innovative drugs. This initiative aims to address industry challenges such as low financing efficiency and poor asset liquidity. The company is also progressing with its IVDD stablecoin program, designed to facilitate efficient cross-border transactions within its ecosystem. These moves are expected to enhance the company’s capital efficiency, accelerate drug development, and bridge the gap between medical innovation and crypto-financial markets.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced a proposed change of its English name to ‘ETHK Labs Inc.’ to better reflect its new strategic positioning and future development direction. This change is part of the company’s evolution into a global high-tech intellectual property capital operation platform, emphasizing a strategy of ‘financing-M&A-integration-exit’ to create sustainable returns for shareholders. The change will not affect shareholders’ rights or the company’s daily operations, and the company will also update its logo to align with the new name.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited announced a change in its audit committee, with Ms. Tai Yang stepping down as a member effective October 20, 2025. This change is part of a broader redesignation of directors and board committee compositions, which may impact the company’s governance and operational oversight.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced the composition of its board of directors and their respective roles and functions. This announcement outlines the structure of the board and its committees, which is crucial for stakeholders to understand the governance and strategic direction of the company.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited, a company incorporated in the Cayman Islands, has announced a significant change in its board structure. Ms. Tai Yang has been redesignated from an independent non-executive director to an executive director, effective October 20, 2025. This change also involves her stepping down from the Remuneration Committee, with Mr. Zhang Jianlei taking her place. The redesignation is part of the company’s strategic adjustments and reflects Ms. Tai’s extensive background in management and finance, which is expected to contribute positively to the company’s operations and governance.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement outlines the structure of the board’s committees, which include the Audit, Remuneration, and Nomination Committees, reflecting the company’s governance framework and potentially impacting its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.